Following our very successful Annual Conference 2018, the following presentations are now available:
Measuring outcomes in Ireland – Prof. Charles Normand, Trinity College
Slaintecare and Value-Based Health Care – Dr. Thomas Kelley ICHOM
HTA as a driver: HIQA’s Health Technology Assessment of Mechanical Thrombectomy in Strokeusing – Dr. Máirín Ryan, Director HTA and Deputy CEO HIQA
Appllying Value Based Health Care to MedTech – Yves Verboven, Director Market Access & Economic Policies, Medtech Europe
CASE STUDIES- How value-based health care strategies are delivering better outcomes
2 Examples from MedTech Europe’s Value-Based Procurement pilot studies
(a) HCB MEAT TAVI Pilot – Ameer Ally Edwards UKI
(b) UniHA – Hypothermia – Kevin Bellenger
Value Based Health care in Wales – Alan Brace, Director of Finance, Health & Social Care, Welsh Government
Assessing the Value of Medical Devices in the HSE – Dr. Anne Dee, Health Technology Assessment Group Lead and Specialist in Public Health Medicine, Department of Public Health
Collaborative approach to Procurement – John Swords, Head of Procurement, Health Business Services, HSE.
IMSTA Annual Conference 2018 will be held on Wednesday 11th April in the CROWN PLAZA HOTEL, Northwood Santry, Dublin 9.
Registration will be avialable shortly on www.imsta.ie.
Sponsorship enquries to email@example.com.
Ltor: Michael Collins, Irish Ambassador to Germany, Dr Tom Kelly – Head of Industrial, Lifesciences and Consumer Division at Enterprise Ireland, Sean Kinsella, PMD Solutions CTO, Anne Dorney, PMD Solutions, CFO, Pat Breen, Minister for Trade, Employment, Business, EU Digital Single Market and Data Protection and Myles Murray, PMD Solution CEO.
Provider of respiratory monitoring technology PMD Solutions has been selected to join the NHS Innovation Accelerator Programme.
The NHS Innovation Programme is a partnership between England’s 15 Academic Health Science Networks (AHSNs) and is focused on working with healthcare innovators.
The announcement from the world’s largest healthcare conference Medica, where PMD Solutions was showcasing its RespiraSense product, a device which can continuously monitor patients’ respiratory rates. The device can help detect patient deterioration up to 12 hours in advance of an adverse patient event, allowing healthcare professionals to intervene faster.
PMD Solutions was invited by Enterprise Ireland to be part of the Irish pavilion where they represented alongside some of the world’s leading medtec organisations.
The NHS will rapidly adopt the company’s RespiraSense product to help improve the standard of care throughout the UK. The device is currently being piloted in Portsmouth, Bradford and London hospitals as part of the Innovation Programme.
RespiraSense is currently awaiting FDA clearance but PMD Solutions expect it to be available for sale within the US sometime next year.
Minister for Trade, Employment, and Business, Pat Breen TD said: “I am delighted but not surprised with PMD Solutions’ recent successes. I had the pleasure of visiting them at this year’s Medica event and was extremely impressed by their high levels of innovation and entrepreneurship. It is wonderful to see an Irish company at the forefront of medical technology advances. They serve as a great example to all Irish companies with ambitions to trade internationally.”
Sheila O’Loughlin, senior market adviser, Enterprise Ireland said: “PMD Solutions has achieved significant traction in the UK market, further strengthened by its recent acceptance on the prestigious NHS Innovation Accelerator Programme. We will continue to support them as they expand in to European and global markets.”
Speaking about the company’s recent successes, Myles Murray, CEO, PMD Solutions said: “We are most grateful to Enterprise Ireland for giving us this fantastic opportunity to showcase RespiraSense to the global healthcare industry. We have created an innovation that is set to change the face of in hospital monitoring at a global scale, improve patient outcomes and generate substantial cost savings for healthcare providers.”
Murray continued: “We are a young company with big ambition. The recent NHS announcement, coupled with Medica has allowed us to engage with global leaders and positioned PMD as an international clinical differentiator in the patient monitoring market.”
With the implementation deadline for the updated MedTech Code of Ethical Business Practice less than 1 month away, IMSTA hosted a Breakfast Briefing to inform members of the two major changes which they should be aware of. Melanie Robertson (Siemens Healthineers), Chairperson of the Code of Ethics Group, kindly updated members of the following changes:
- Stopping Direct Sponsorship to Healthcare Practitioners (HCPs). As of January 1, 2018, it will no longer be allowed for companies to provide direct financial support to individual HCPs to attend either local or international Third Party Organised Events (e.g. congresses). Instead, support can be offered through Educational Grants provided to Healthcare Organisations (HCOs) or Professional Conference Organisers (PCOs). The message here was very clear that Education Grants can only be provided to Healthcare Organisations or PCOs, and member companies cannot themselves select the person who should be the recipient of this Grant. They can however suggest a specific area of expertise who should benefit from the Grant.
- Public disclosure by Member Companies of their Educational Grants: as of January 1, 2018, companies providing Educational Grants to HCOs will be publicly disclosing the aggregated amount of all Educational Grants, provided to HCOs over the year of 2017, on the Transparent MedTech system. The disclosure deadline is 30 June 2018, for publication in August.
IMSTA Members can avail of templates etc which are available on the Med Tech Europe website by following the link here. Melanie also included some useful information which should assist the smooth adaption of the changes in her slide presentation available on request from firstname.lastname@example.org. This included information on how to navigate the MedTech Europe Conference Vetting System (CVS). This Conference Vetting System is an independently managed system that reviews the compliance of third-party educational conferences with the MTE Code of Ethical Business Practice, based on clear and objective criteria. For more information on this please see Med Tech Europe link above.
If any member would like more information or have any comments to make on the changes to the Code of Ethical Business Practice, please email email@example.com .
MED TECH Europe have shared the attached HAI updated brochure. It is important to note that this is a revamp and update of an already existing information sheet, with new data, new calls for action (in line with our position paper) and a clear link made between AMR and HAIs. The brochure showcases the different medical technologies that can prevent and control HAIs throughout the patient pathway.
IMSTA SUBMISSION to Public consultation on draft guidance document relating to distribution of medical devices (including IVDs) completed.
Please follow links to view documents:
“This is a must see event for IMSTA members who want to compete for MES contracts in the future.”
THE FOLLOWING PRESENTATIONS ARE NOW AVAILABLE:
MES SEMINAR – Friday 21st April 2017
Registration – 10.00 to 10.30 a.m.
Venue – The Emmet Theatre, ARTS Building, TRINITY COLLEGE, Dublin 2.
No parking at venue, parking nearby in Setanta Centre.
Enter via Nassau Street Entrance.
For late registrations please contact Joanne on firstname.lastname@example.org
See Agenda here :MES Seminar Agenda
Justin Carty, CEO of IMSTA spoke with Irish Times journalist Sylvia Thompson
The cheapest product rarely gives customers the best value, according to Justin Carty, the CEO of the Irish Medical and Surgical Trade Association. Representing products ranging from bandages to CAT scans, Carty has to navigate a careful route when promoting the medical device industry to public and private hospital purchasers keen to get the best value for money with limited budgets.
But, as luck would have it, Carty’s agenda fits completely with the new EU public procurement directive. This 2014 EU directive presents a holistic analysis of value based health care which evaluates the entire life cycle, safety and effectiveness of products and not just the purchasing price. It also encourages the industry to define best price-quality ratio and to collaborate more closely with purchasers at the pre-tendering phase.
A recent report from the Boston Consulting Group, commissioned by Med Tech Europe (of which IMTSA is a member) presents a clear picture on how things need to change. Currently, most health care providers purchase medical products on the basis of the up-front purchase price, which, the consultants argue cloud the true cost of care.
The report includes insightful examples of what happens when broader criteria are used to purchase equipment. Take for instance, the Karolinska University Hospital in Sweden whose foutreen year tender for imaging services which included MRI, ultrasound and CT scanners; by tendering for imaging services rather than equipment, the contract included maintenance of technical standards, upgrades and replacement during the fourteen year period. Similarly, when the Stockholm County Council (which runs most of the city’s hospitals) sought tenders for wound care products, it asked suppliers to include calculations for the number of dressing changes, staff and transportation costs for changing these dressings. The winning bid was from the highest priced products which showed a lower cost of care over time.
The Boston Consulting Group report argues that smarter procurement such as these examples embraces a value-based framework that is aligned with the new EU directive. To include all the hidden costs of the equipment in terms of its durability and suitability to patient’s needs, the group suggests a calculation based on patient outcomes divided by the costs of achieving these outcomes.
Carty hopes this more holistic approach to procurement will be embraced by healthcare providers in Ireland. “This new procurement process focuses more on how to achieve better patient outcomes,” he says. Carty also suggests it would encourage clinicians to work more closely with the medical technology industry rather than leaving procurement decisions to those with their eyes firmly placed on the purchase price alone.
A natural extension of this approach would, according to Carty, be for healthcare providers to seek solutions to ongoing problems through industry competitions. This already happens in some countries such as the UK where the Small Business Innovation Research (SBIR) mechanism is used. There, NHS England’s SBRI Healthcare has worked with companies to come up with new solutions to problems in diverse areas such as diabetic foot ulcers, child and adolescent mental health and brain injury. The key element of effective SBIR programmes is that clinicians and front-line staff are the ones to identify the unmet need.
In his role as CEO of IMSTA, Carty proposed the SBIR model to a cross-departmental committee at Government level in 2015.
“We proposed that one to two per cent of the HSE non-pay procurement budget of €500 million could be ring-fenced to find solutions to identified healthcare problems,” he explains. The proposal was repeated in the IMSTA submission to the Oireachtas Committee on the Future of Healthcare in August 2016. As yet, the model hasn’t been embraced by the Health Services Executive.
Now, in 2017, Carty is keen to move the agenda forwards. To that end, Value-Based Healthcare Strategies is the theme of the IMSTA Annual Conference in the Crown Plaza Hotel, Santry on March 22. Confirmed speakers include Dr Tom Kelley from ICHOM, the International Consortium for Health Outcomes Measurement, Bill Maher, the CEO of the Bons Secours Hospital Group and Frank Sullivan, Adjunct Professor in Medicine and Director of Prostate Cancer Institute, NUIG. Throughout the conference, delegates will hear about the role of healthcare innovation in improving patient and clinical outcomes. Proposals for a new economic evaluation framework for medtech will also be discussed.
Ultimately, Carty is keen to spread the message about the role of medical technology companies in helping people live longer, healthier and more productive lives. “These life changing innovations also bring savings across the health care system by replacing more expensive procedures, reducing hospital stays and allowing people to return to work and home more quickly,” says Carty.
However, he adds a note of caution. “In order to understand the value and benefits of medical technology and ensure continued leadership of this industry, we must have the right public policies to support investment, innovation and patient access.”
Article for IMSTA Newsletter, Spring 2017
IMSTA’s Annual Conference 2017 highlighted the ‘VALUE of medtech’ in achieving quality patient outcomes. Defining ‘value’ in health care is currently trending world-wide, not only from an industry perspective – pharma, medtech and ICT, healthcare providers, clinical communities and academia are all endeavouring to articulate what ‘value’ means to them and how to apply or implement “value-based health care”.
The following presentations are now available for viewing:
“Optimising the Value of medical equipment through implementing holistic equipment management” Mr. Fran Hegarty, Children’s Hospital Group